Biocardia, Inc. 8-K Filing
Ticker: BCDA · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0000925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Biocardia, Inc. (ticker: BCDA) to the SEC on Apr 2, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 B (h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat).
How long is this filing?
Biocardia, Inc.'s 8-K filing is 2 pages with approximately 534 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2026-04-02 09:00:11
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20260402_8k.htm (8-K) — 30KB
- ex_940999.htm (EX-99.1) — 10KB
- 0001437749-26-010967.txt ( ) — 171KB
- bcda-20260402.xsd (EX-101.SCH) — 3KB
- bcda-20260402_def.xml (EX-101.DEF) — 11KB
- bcda-20260402_lab.xml (EX-101.LAB) — 15KB
- bcda-20260402_pre.xml (EX-101.PRE) — 11KB
- bcda20260402_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 2, 2026, BioCardia, Inc. issued a press release reporting submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP System for ischemic chronic heart failure with reduced ejection fraction (HFrEF). A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated April 2, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: April 2, 2026